Diabetes Guidelines in View of Recent Clinical Trials Are They Still Applicable?
|
|
- Kristina Welch
- 5 years ago
- Views:
Transcription
1
2 Diabetes Guidelines in View of Recent Clinical Trials Are They Still Applicable? Jay S. Skyler, MD, MACP Division of Endocrinology, Diabetes, and Metabolism and Diabetes Research Institute University of Miami Miller School of Medicine
3 Diabetes Treatment Components Aspirin/Anti-Platelet Therapy Blood Pressure Control Cholesterol Control Statin Therapy Diet Exercise Fat Decrease Body Weight Glucose Control
4 Recommendations for BP and Lipids BP measurement BP targets Lipid measurements LDL target Triglyceride target HDL target ADA At every visit IDF Annually (at every visit if above target) ESC/EASD <130/80 mmhg <130/80 mmhg <130/80 mmhg Annually 100 mg/dl (2.6 mmol/l) 150 mg/dl (1.7 mmol/l) male >40 mg/dl (>1.0 mmol/l) female >50 mg/dl (>1.3 mmol/l) Annually - <95 mg/dl (2.5 mmol/l) <200 mg/dl (<2.3 mmol/l) >39 mg/dl (>1.0 mmol/l) - <70 mg/dl (1.8 mmol/l) <150 mg/dl (<1.7 mmol/l) male >40 mg/dl (>1.0 mmol/l) female >46 mg/dl (>1.2 mmol/l) IDF Clinical Guidelines Task Force. Brussels, ADA. Diabetes Care 2009; 31(Suppl. 1):S Ryden L, et al. Eur Heart J 2007; 28:
5 A1c Targets in Current Guidelines ADA/EASD <7 IDF 6.5 NICE <6.5 ACE/AACE 6.5 France <6.5* Canada Australia A1c target (%) 7 7 Latin America <6.5 * If on single or double therapy; if on triple therapy or insulin, n, then A1c <7%
6 American Diabetes Association. Diabetes Care 2009; 32 (suppl 1):S13 :S13-S61S61
7 2009 ADA Treatment Goals in Diabetes A1c <7.0%* Blood pressure LDL-cholesterol <130/80 mmhg <100 mg/dl (2.6 mmol/l) or <70 mg/dl (1.8 mmol/l) (or ~30-40% reduction from baseline) Serum triglycerides <150 mg/dl (1.7 mmol/l) HDL cholesterol Smoking cessation Aspirin therapy Men: >40 mg/dl Women: >50 mg/dl mg/dl (1.04 mmol/l) mg/dl (1.3 mmol/l) Yes If history (or increased risk) of cardiovascular disease American Diabetes Association. Diabetes Care. 2009; 32 (suppl 1):S13 :S13-S61S61
8 2009; Issue 3
9 Cochrane Review Treating patients to lower than standard BP targets, /90 160/ mmhg, does not reduce mortality or morbidity. Because guidelines are recommending even lower targets for diabetes mellitus and chronic renal disease, we are currently conducting systematic reviews in those groups of patients. 2009; Issue 3
10 Relative risk of CHD in BP trials according to pretreatment DBP and SBP Law, M R et al. BMJ 2009;338:b1665
11 Relative risk of stroke in BP trials according to pretreatment DBP and SBP Law, M R et al. BMJ 2009;338:b1665
12 Reduction in incidence of CHD & stroke in relation to reduction in DBP and age Law, M R et al. BMJ 2009;338:b1665
13 Reduction in incidence of CHD & stroke in relation to reduction in SBP and age Law, M R et al. BMJ 2009;338:b1665
14 Blood Pressure Should the target BP be 110/70? Should all persons be treated with anti-hypertensive agents regardless of BP? Law, M R et al. BMJ 2009;338:b1665
15 Effect of ACE or ARB Rx on Diabetic Retinopathy Effects of Enalapril and Losartan on Retinopathy, as Measured by the Odds Ratio of Progression, during the Five-Year Follow-up Period Mauer M et al. N Engl J Med 2009;361:40-51
16 2009 ADA Treatment Goals in Diabetes A1c <7.0%* Blood pressure LDL-cholesterol <130/80 mmhg <100 mg/dl (2.6 mmol/l) or <70 mg/dl (1.8 mmol/l) (or ~30-40% reduction from baseline) Serum triglycerides <150 mg/dl (1.7 mmol/l) HDL cholesterol Smoking cessation Aspirin therapy Men: >40 mg/dl Women: >50 mg/dl mg/dl (1.04 mmol/l) mg/dl (1.3 mmol/l) Yes If history (or increased risk) of cardiovascular disease American Diabetes Association. Diabetes Care. 2009; 32 (suppl 1):S13 :S13-S61S61
17 Lipids If drug-treated patients do not reach targets on maximal tolerated statin therapy, a reduction in LDL cholesterol of 30 40% from baseline is an alternative therapeutic goal American Diabetes Association. Diabetes Care. 2009; 32 (suppl 1):S13 :S13-S61S61
18 Lipids Statin therapy should be added to lifestyle therapy, regardless of baseline lipid levels, for diabetic patients: with overt CVD (A) without CVD who are over the age of 40 and have one or more other CVD risk factors. (A) American Diabetes Association. Diabetes Care. 2009; 32 (suppl 1):S13 :S13-S61S61
19 Statins for Primary Prevention Brugts, J J et al. BMJ 2009;338:b2376
20 Statins for Primary Prevention Brugts, J J et al. BMJ 2009;338:b2376
21 2009 ADA Treatment Goals in Diabetes A1c <7.0%* Blood pressure LDL-cholesterol <130/80 mmhg <100 mg/dl (2.6 mmol/l) or <70 mg/dl (1.8 mmol/l) (or ~30-40% reduction from baseline) Serum triglycerides <150 mg/dl (1.7 mmol/l) HDL cholesterol Smoking cessation Aspirin therapy Men: >40 mg/dl Women: >50 mg/dl mg/dl (1.04 mmol/l) mg/dl (1.3 mmol/l) Yes If history (or increased risk) of cardiovascular disease American Diabetes Association. Diabetes Care. 2009; 32 (suppl 1):S13 :S13-S61S61
22 Anti-Platelet Therapy Revision Use aspirin therapy ( mg/day) as a primary prevention strategy in those with T1D or T2D at increased CVD risk, including those >40 years old or with additional risk factors (family history of CVD, hypertension, smoking, dyslipidemia, or albuminuria) For patients with CVD and aspirin allergy, clopidogrel (75 mg/day) should be used Combination therapy with aspirin ( mg/day) and clopidogrel (75 mg/day) is reasonable for up to 1 year after an acute coronary episode American Diabetes Association. Diabetes Care. 2009; 32 (suppl 1):S13 :S13-S61S61
23 Aspirin for Primary Prevention serious vascular events dropped from 0 57% to 0 51% 0 per year by the use of aspirin risk of major bleeds increased from 0 07% 0 07% to 0 10% 0 per year by the use of aspirin. Antithrombotic Trialists (ATT) Collaboration; Lancet 2009; 373:
24 Serious Vascular Events Antithrombotic Trialists (ATT) Collaboration; Lancet 2009; 373:
25 2009 ADA Treatment Goals in Diabetes A1c <7.0%* Blood pressure LDL-cholesterol <130/80 mmhg <100 mg/dl (2.6 mmol/l) or <70 mg/dl (1.8 mmol/l) (or ~30-40% reduction from baseline) Serum triglycerides <150 mg/dl (1.7 mmol/l) HDL cholesterol Smoking cessation Aspirin therapy Men: >40 mg/dl Women: >50 mg/dl mg/dl (1.04 mmol/l) mg/dl (1.3 mmol/l) Yes If history (or increased risk) of cardiovascular disease American Diabetes Association. Diabetes Care. 2009; 32 (suppl 1):S13 :S13-S61S61
26 Targets for Glycemic Control* ADA Target (for patients in general) A1C < 7.0% Normal A1C < 6.0% ADA 2006: The A1C goal for the individual patient is an A1C as close to normal (<6%) as possible without significant hypoglycemia Realistic target: lowest A1C level possible without unacceptable adverse effects *DCCT referenced assays: normal range 4% 6%. American Diabetes Association. Diabetes Care. 2008; 31 (suppl 1):S13 :S13-S54. S54.
27 American Diabetes Association. Diabetes Care 2009; 32 (suppl 1):S13 :S13-S61S61
28
29 Impact of Intensive Therapy in Diabetes Summary of Major Clinical Trials Study Microvascular CVD Mortality DCCT/EDIC UKPDS ACCORD? ADVANCE VADT UKPDS / UKPDS fu UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352: Holman RR. N Engl J Med Oct 9;359(15): DCCT / EDIC DCCT Research Group. N Engl J Med 329; , 1993 Nathan DM, et al. N Engl J Med. 2005;353: ACCORD Gerstein HC, et al. N Engl J Med. 2008;358: ADVANCE Patel A, et al. N Engl J Med. 2008;358: VADT Duckworth W et al. N Engl J Med 2009;360 Initial Trial Long Term Follow-up
30 Effect of more vs less intensive control of glucose on Non-Fatal Myocardial Infarction Study Odds Ratio (95% CI) Weight (%) UKPDS PROactive ADVANCE VADT ACCORD Overall 0.78 (0.62, 0.98) 0.83 (0.64, 1.06) 0.98 (0.78, 1.23) 0.81 (0.58, 1.15) 0.78 (0.64, 0.95) 0.83 (0.75, 0.93) I-squared = 0% (95% CI 0% to 69.3%), p = Odds Ratio Intensive therapy better Standard therapy better Ray KK et al; Lancet 2009; 373:
31 Effect of more vs less intensive control of glucose on Coronary Heart Disease Study Odds Ratio (95% CI) Weight (%) UKPDS PROactive* ADVANCE VADT ACCORD Overall 0.75 (0.54, 1.04) 0.81 (0.65, 1.00) 0.92 (0.78, 1.07) 0.85 (0.62, 1.17) 0.82 (0.68, 0.99) 0.85 (0.77, 0.93) I-squared = 0% (95% CI 0% to 53%), p = Intensive therapy better Odds Ratio Standard therapy better Ray KK et al; Lancet 2009; 373:
32 Effect of more vs less intensive control of glucose on Stroke Study Odds Ratio (95% CI) Weight (%) UKPDS PROactive* ADVANCE VADT* ACCORD Overall I-squared = 0% (95% CI 0% to 62%), p = (0.51, 1.61) 0.81 (0.60, 1.08) 0.97 (0.81, 1.16) 0.78 (0.47, 1.28) 1.05 (0.76, 1.46) 0.93 (0.81, 1.06) Odds Ratio Intensive therapy better Standard therapy better Ray KK et al; Lancet 2009; 373:
33 Effect of more vs less intensive control of glucose on Death Study Odds Ratio (95% CI) Weight (%) UKPDS PROactive ADVANCE VADT ACCORD Overall I-squared = 58% (95% CI 0% to 84%), p = (0.53, 1.20) 0.96 (0.77, 1.19) 0.93 (0.82, 1.05) 1.09 (0.81, 1.47) 1.28 (1.06, 1.54) 1.02 (0.87, 1.19) Intensive therapy better Odds Ratio Standard therapy better Ray KK et al; Lancet 2009; 373:
34 Intensive Glycemic Control in Diabetes: Implications of ACCORD, ADVANCE and VADT A1C targets for diabetes Lowering A1C to < 7% has been shown to significantly reduce the risk of microvascular complications in both type 1 and type 2 diabetes Controlled trials of more intensive glycemic control have not shown a decrease in CVD risk Long-term follow-up suggests that A1C < 7% in the years following diagnosis is associated with a reduction in CVD risk Until more evidence becomes available, the general A1C target of < 7% appears reasonable For some patients, individualized glycemic targets may be appropriate riate For CVD risk reduction in patients with diabetes: Continue to follow evidence-based recommendations for BP, lipids, aspirin, tobacco A position statement of the ADA and a scientific statement of the e ACC and the AHA. Diabetes Care 32; 2009;
35 Conclusions & Implications Comprehensive care involves treatment of all modifiable CVD risk factors DCCT and UKPDS follow-up studies demonstrate intensive glycemic control reduces micro- and macrovascular disease Glycemic control seems to provide CVD benefit if initiated early in the disease course Intensive treatment of BP and lipids reduces the impact of glycemic control on micro- and macrovascular complications
36 Conclusions & Implications Glycemic goals for most patients should remain unchanged, i.e. targeting A1C <7% Higher A1C targets are acceptable for patients with hypoglycemia unawareness and/or a known history of severe hypoglycemia, established CVD, and in older frail patients Lower A1C targets are appropriate in patients with shorter duration of diabetes and those without established CVD
37 Benefit of different interventions per 200 diabetic pts treated for 5 years 5 0 Per 4mmHg lower SBP Per 1mmol/L lower LDL-C (38.7 mg/dl) Per 0.9% lower A1c CV events Ray KK et al; Lancet 2009; 373:
38 2009 ADA Treatment Goals in Diabetes A1c <7.0%* Blood pressure LDL-cholesterol <130/80 mmhg <100 mg/dl (2.6 mmol/l) or <70 mg/dl (1.8 mmol/l) (or ~30-40% reduction from baseline) Serum triglycerides <150 mg/dl (1.7 mmol/l) HDL cholesterol Smoking cessation Aspirin therapy Men: >40 mg/dl Women: >50 mg/dl mg/dl (1.04 mmol/l) mg/dl (1.3 mmol/l) Yes If history (or increased risk) of cardiovascular disease American Diabetes Association. Diabetes Care. 2009; 32 (suppl 1):S13 :S13-S61S61
39 A1c Not the Whole Story
40 A1C and estimated Average Glucose - eag Formula: 28.7 X A1C 46.7 = eag (mg/dl) Nathan et al. Diabetes Care 31: , 1478, 2008
41 A1C and eag not tell whole story 300 Blood Glucose Control mg/dl AM 10 AM 2 PM 6 PM 10 PM Time of Day 2 AM High postprandial glucoses and glucose variability correlate with poor outcomes but there is not proof that treating to reduce PPG or variability improves outcome
42 Glycemia Treatment Algorithms
43 IDF Type 2 DM Treatment Algorithm Lifestyle Intervention A1c >6.5% Monotherapy If Renal Impairment or Heart Failure Sulfonylurea If A1c >6.5% If Intolerance Dual Therapy + SU or MET or TZD If A1c >6.5% Triple Therapy SU+MET or MET+TZD + TZD or SU If A1c >7.5% Insulin Therapy SU + MET + Once Daily Basal Insulin IDF. Global Guideline for Type 2 Diabetes. Available from:
44 Previous ADA/EASD Treatment Algorithm Lifestyle intervention + metformin If A1c 7% Add basal insulin (most effective) Add sulfonylurea (least expensive) Add glitazone (no hypoglycemia) If A1c 7% If A1c 7% If A1c 7% Intensify insulin Add glitazone Add basal insulin Add sulfonylurea If A1c 7% If A1c 7% Add basal or intensify insulin Intensive insulin + metformin +/- glitazone Nathan DM, et al. Diabetes Care 2008; 31:173 5.
45 Diabetes Care. 2009; 32:
46 2009 ADA/EASD Consensus Algorithm Revised Treatment Algorithm STEP 1 At diagnosis: Lifestyle + Metformin STEP 2 1 st Add Basal insulin st Tier* Add Sulfonylurea HbA1C >7.0% 2 nd nd Tier Add GLP 1 1 agonist Add Pioglitazone STEP 3 Intensive insulin *1 st Tier: Well validated core therapies. 2 nd Tier: Less well validated therapies. Nathan DM et al. Diabetes Care. 2009; 32:
47 Pathophysiologic-Based Algorithm Lifestyle + Triple Combination: TZD + Metformin + Exenatide A1c < 6.0% Ralph DeFronzo, Banting Lecture, ADA Annual Meeting 2008.
48 Comparison of Treatment Algorithms Durability β Cell Preservation Hypoglycemia Weight Gain ADA No No Yes Yes Pathophysiologic- Based Yes Yes No No Ralph DeFronzo, Banting Lecture, ADA Annual Meeting 2008.
49 2009 ADA/EASD Consensus Algorithm Revised Treatment Algorithm STEP 1 At diagnosis: Lifestyle + Metformin STEP 2 1 st Add Basal insulin st Tier* Add Sulfonylurea HbA1C >7.0% 2 nd nd Tier Add GLP 1 1 agonist Add Pioglitazone STEP 3 Intensive insulin *1 st Tier: Well validated core therapies. 2 nd Tier: Less well validated therapies. Nathan DM et al. Diabetes Care. 2009; 32:
50 UKPDS - A1c 9 CONVENTIONAL GROUP A1c, % 8 7 INTENSIVE GROUP YEARS ukpds Lancet 1998; 352:
51 UKPDS: Change in Body Weight CHANGE IN WEIGHT (kg) Cross-Sectional, Mean Values INTENSIVE GROUP CONVENTIONAL GROUP YEARS ukpds Lancet 1998; 352:
52 2009 ADA/EASD Consensus Algorithm Revised Treatment Algorithm STEP 1 At diagnosis: Lifestyle + Metformin STEP 2 1 st Add Basal insulin st Tier* Add Sulfonylurea HbA1C >7.0% 2 nd nd Tier Add GLP 1 1 agonist Add Pioglitazone STEP 3 Intensive insulin *1 st Tier: Well validated core therapies. 2 nd Tier: Less well validated therapies. Nathan DM et al. Diabetes Care. 2009; 32:
53 ADOPT - A1c Over Time Glyburide Metformin % 7.0 Rosiglitazone Time (years) NEJM 2006; 355:
54 DPP4 Inhibitors vs Sulfonylureas DPP4 Inhibitors Glucose dependent insulin secretion Modulation of glucagon secretion No weight gain No hypoglycemia??? Side effects $$$ Sulfonylureas Insulin secretion not glucose dependent No effect Weight gain Hypoglycemia Black box warning
55 2009 ADA/EASD Consensus Algorithm Revised Treatment Algorithm STEP 1 At diagnosis: Lifestyle + Metformin STEP 2 1 st Add Basal insulin st Tier* Add Sulfonylurea HbA1C >7.0% 2 nd nd Tier Add GLP 1 1 agonist Add Pioglitazone STEP 3 Intensive insulin *1 st Tier: Well validated core therapies. 2 nd Tier: Less well validated therapies. Nathan DM et al. Diabetes Care. 2009; 32:
56 2009 ADA/EASD Consensus Algorithm Revised Treatment Algorithm STEP 1 At diagnosis: Lifestyle + Metformin Introduced in 1957 STEP 2 1 st Add Basal insulin st Tier* Add Sulfonylurea Introduced in 1950s HbA1C >7.0% 2 nd nd Tier Add GLP 1 1 agonist Add Pioglitazone STEP 3 Introduced in 1922 Intensive insulin *1 st Tier: Well validated core therapies. 2 nd Tier: Less well validated therapies. Nathan DM et al. Diabetes Care. 2009; 32:
57 2009 ADA/EASD Consensus Algorithm Revised Treatment Algorithm STEP 1 At diagnosis: Lifestyle + Metformin STEP 2 1 st Add Basal insulin st Tier* Add Sulfonylurea Cause Weight HbA1C >7.0% Gain!! 2 nd nd Tier Add GLP 1 1 agonist Add Pioglitazone STEP 3 Intensive insulin *1 st Tier: Well validated core therapies. 2 nd Tier: Less well validated therapies. Nathan DM et al. Diabetes Care. 2009; 32:
58 2009 ADA/EASD Consensus Algorithm Revised Treatment Algorithm STEP 1 At diagnosis: Lifestyle + Metformin STEP 2 1 st Add Basal insulin st Tier* Add Sulfonylurea HbA1C >7.0% 2 nd nd Tier Add GLP 1 1 agonist Add Pioglitazone STEP 3 Intensive insulin *1 st Tier: Well validated core therapies. 2 nd Tier: Less well validated therapies. Nathan DM et al. Diabetes Care. 2009; 32:
59 Skyler Algorithm 2009 Lifestyle Metformin? + DPP4 Exenatide Basal insulin
60 Diabetes Treatment Components Aspirin/Anti-Platelet Therapy Blood Pressure Control Cholesterol Control Statin Therapy Diet Exercise Fat Decrease Body Weight Glucose Control
61
Diabetes Mellitus: A Cardiovascular Disease
Diabetes Mellitus: A Cardiovascular Disease Nestoras Mathioudakis, M.D. Assistant Professor of Medicine Division of Endocrinology, Diabetes, & Metabolism September 30, 2013 1 The ABCs of cardiovascular
More informationOral Hypoglycemics and Risk of Adverse Cardiac Events: A Summary of the Controversy
Oral Hypoglycemics and Risk of Adverse Cardiac Events: A Summary of the Controversy Jeffrey Boord, MD, MPH Advances in Cardiovascular Medicine Kingston, Jamaica December 7, 2012 VanderbiltHeart.com Outline
More informationUpdate on CVD and Microvascular Complications in T2D
Update on CVD and Microvascular Complications in T2D Jay S. Skyler, MD, MACP Division of Endocrinology, Diabetes, and Metabolism and Diabetes Research Institute University of Miami Miller School of Medicine
More informationObesity, Insulin Resistance, Metabolic Syndrome, and the Natural History of Type 2 Diabetes
Obesity, Insulin Resistance, Metabolic Syndrome, and the Natural History of Type 2 Diabetes Genetics, environment, and lifestyle (obesity, inactivity, poor diet) Impaired fasting glucose Decreased β-cell
More informationESC GUIDELINES ON DIABETES AND CARDIOVASCULAR DISEASES
ESC GUIDELINES ON DIABETES AND CARDIOVASCULAR DISEASES Pr. Michel KOMAJDA Institute of Cardiology - IHU ICAN Pitie Salpetriere Hospital - University Pierre and Marie Curie, Paris (France) DEFINITION A
More informationDisclosures. Diabetes and Cardiovascular Risk Management. Learning Objectives. Atherosclerotic Cardiovascular Disease
Disclosures Diabetes and Cardiovascular Risk Management Tony Hampton, MD, MBA Medical Director Advocate Aurora Operating System Advocate Aurora Healthcare Downers Grove, IL No conflicts or disclosures
More informationThe Diabetes Link to Heart Disease
The Diabetes Link to Heart Disease Anthony Abe DeSantis, MD September 18, 2015 University of WA Division of Metabolism, Endocrinology and Nutrition Oswald Toosweet Case #1 68 yo M with T2DM Diagnosed DM
More informationA Fork in the Road: Navigating Through New Terrain
A Fork in the Road: Navigating Through New Terrain Carol Hatch Wysham, MD Clinical Associate Professor of Medicine University of Washington School of Medicine Section Head, Rockwood Center for Diabetes
More informationGlycemic control a matter of life and death
Glycemic control a matter of life and death Linda Garcia Mellbin MD PhD Specialist in Cardiology & Internal medicine Dep of Cardiology Karolinska University Hospital /Karolinska Institutet Mortality (%)
More informationHanyang University Guri Hospital Chang Beom Lee
Hanyang University Guri Hospital Chang Beom Lee Meal prayer, Van Brekelenkam 17 th C Introduction 2012 ADA/EASD Position Statement Proper Patients for Pioglitazone β-cell Preservation by Pioglitazone Benefit
More informationSlide 1. Slide 2. Slide 3. A Fork in the Road: Navigating Through New Terrain. Diabetes Standards of Care Then and Now
Slide 1 A Fork in the Road: Navigating Through New Terrain Carol Hatch Wysham, MD Clinical Associate Professor of Medicine University of Washington School of Medicine Section Head, Rockwood Center for
More informationThe Clinical Unmet need in the patient with Diabetes and ACS
The Clinical Unmet need in the patient with Diabetes and ACS Professor Kausik Ray (UK) BSc(hons), MBChB, MD, MPhil, FRCP (lon), FRCP (ed), FACC, FESC, FAHA Diabetes is a global public health challenge
More informationDiabetes Day for Primary Care Clinicians Advances in Diabetes Care
Diabetes Day for Primary Care Clinicians Advances in Diabetes Care Elliot Sternthal, MD, FACP, FACE Chair New England AACE Diabetes Day Planning Committee Welcome and Introduction This presentation will:
More informationDiabetes Mellitus: Implications of New Clinical Trials and New Medications
Diabetes Mellitus: Implications of New Clinical Trials and New Medications Estimates of Diagnosed Diabetes in Adults, 2005 Alka M. Kanaya, MD Asst. Professor of Medicine UCSF, Primary Care CME October
More informationIMPROVED DIAGNOSIS OF TYPE 2 DIABETES AND TAILORING MEDICATIONS
IMPROVED DIAGNOSIS OF TYPE 2 DIABETES AND TAILORING MEDICATIONS Dr Bidhu Mohapatra, MBBS, MD, FRACP Consultant Physician Endocrinology and General Medicine Introduction 382 million people affected by diabetes
More informationPractical Diabetes. Nic Crook. (and don t use so many charts) Kuirau Specialists 1239 Ranolf Street Rotorua. Rotorua Hospital Private Bag 3023 Rotorua
Practical Diabetes (and don t use so many charts) Nic Crook Rotorua Hospital Private Bag 3023 Rotorua Kuirau Specialists 1239 Ranolf Street Rotorua Worldwide rates of diabetes mellitus: predictions 80
More informationAmerican Diabetes Association 2018 Guidelines Important Notable Points
American Diabetes Association 2018 Guidelines Important Notable Points The Standards of Medical Care in Diabetes-2018 by ADA include the most current evidencebased recommendations for diagnosing and treating
More informationGlycemic control what can be achieved with life-style and when and how to use pharmacological agents?
Glycemic control what can be achieved with life-style and when and how to use pharmacological agents? Eberhard Standl Munich Diabetes Research Institute At the Munich Helmholtz Center Pathogenetic key
More informationACCORD, ADVANCE & VADT. Now what do I do in my practice?
ACCORD, ADVANCE & VADT Now what do I do in my practice? Richard M. Bergenstal, MD International Diabetes Center Park Nicollet Health Services University of Minnesota Minneapolis, MN richard.bergenstal@parknicollet.com
More informationComprehensive Diabetes Treatment
Comprehensive Diabetes Treatment Joshua L. Cohen, M.D., F.A.C.P. Professor of Medicine Interim Director, Division of Endocrinology & Metabolism The George Washington University School of Medicine Diabetes
More informationHow to Reduce CVD Complications in Diabetes?
How to Reduce CVD Complications in Diabetes? Chaicharn Deerochanawong M.D. Diabetes and Endocrinology Unit Department of Medicine Rajavithi Hospital, Ministry of Public Health Framingham Heart Study 30-Year
More informationDiabetes new challenges, new agents, new order
Diabetes new challenges, new agents, new order Ken Earle St Georges University Hospitals NHS Foundation Trust Overview Cardiovascular disease unmet needs Treating evident and residual risk Integrating
More informationInitiating Insulin in Primary Care for Type 2 Diabetes Mellitus. Dr Manish Khanolkar, Diabetologist, Auckland Diabetes Centre
Initiating Insulin in Primary Care for Type 2 Diabetes Mellitus Dr Manish Khanolkar, Diabetologist, Auckland Diabetes Centre Outline How big is the problem? Natural progression of type 2 diabetes What
More informationThe ABCs (A1C, BP and Cholesterol) of Diabetes
The ABCs (A1C, BP and Cholesterol) of Diabetes Gregg Simonson, PhD Director, Professional Training and Consulting International Diabetes Center; Adjunct Assistant Professor, University of Minnesota Department
More informationEvidence-Based Glucose Management in Type 2 Diabetes
Evidence-Based Glucose Management in Type 2 Diabetes James R. Gavin III, MD, PhD CEO and Chief Medical Officer Healing Our Village, Inc. Clinical Professor of Medicine Emory University School of Medicine
More informationSCIENTIFIC STUDY REPORT
PAGE 1 18-NOV-2016 SCIENTIFIC STUDY REPORT Study Title: Real-Life Effectiveness and Care Patterns of Diabetes Management The RECAP-DM Study 1 EXECUTIVE SUMMARY Introduction: Despite the well-established
More informationCurrent Diabetes Care for Internists:2011
Current Diabetes Care for Internists:2011 Petch Rawdaree, DM, MSc, DLSHTM Faculty of Medicine Vajira Hospital University of Bangkok Metropolis 19 th January 2011 ก ก 1. ก ก ก ก 2. ก ก ก ก ก 3. ก ก ก ก
More informationDiabete: terapia nei pazienti a rischio cardiovascolare
Diabete: terapia nei pazienti a rischio cardiovascolare Giorgio Sesti Università Magna Graecia di Catanzaro Cardiovascular mortality in relation to diabetes mellitus and a prior MI: A Danish Population
More informationDiabetes Treatment Update
Diabetes Treatment Update Timothy C. Evans, MD PhD FACP University of Washington Department of Medicine Disclosure: Dr. Evans has no significant financial interest in any of the products or manufacturers
More informationDiabetes and the Heart
Diabetes and the Heart Jeffrey Boord, MD, MPH Advances in Cardiovascular Medicine Kingston, Jamaica December 6, 2012 Outline Screening for diabetes in patients with CAD Screening for CAD in patients with
More informationMae Sheikh-Ali, M.D. Assistant Professor of Medicine Division of Endocrinology University of Florida College of Medicine- Jacksonville
Mae Sheikh-Ali, M.D. Assistant Professor of Medicine Division of Endocrinology University of Florida College of Medicine- Jacksonville Pathogenesis of Diabetes Mellitus (DM) Criteria for the diagnosis
More informationWhat s New in Type 2? Peter Hammond Consultant Physician Harrogate District Hospital
What s New in Type 2? Peter Hammond Consultant Physician Harrogate District Hospital Therapy considerations in T2DM Thiazoledinediones DPP IV inhibitors GLP 1 agonists Insulin Type Delivery Horizon scanning
More informationChief of Endocrinology East Orange General Hospital
Targeting the Incretins System: Can it Improve Our Ability to Treat Type 2 Diabetes? Darshi Sunderam, MD Darshi Sunderam, MD Chief of Endocrinology East Orange General Hospital Age-adjusted Percentage
More informationDiabetes and Cardiovascular Risk Management Denise M. Kolanczyk, PharmD, BCPS-AQ Cardiology
Diabetes and Cardiovascular Risk Management Denise M. Kolanczyk, PharmD, BCPS-AQ Cardiology Disclosures In compliance with the accrediting board policies, the American Diabetes Association requires the
More informationMacrovascular Residual Risk. What risk remains after LDL-C management and intensive therapy?
Macrovascular Residual Risk What risk remains after LDL-C management and intensive therapy? Defining Residual Vascular Risk The risk of macrovascular events and microvascular complications which persists
More informationMicrovascular Disease in Type 1 Diabetes
Microvascular Disease in Type 1 Diabetes Jay S. Skyler, MD, MACP Division of Endocrinology, Diabetes, and Metabolism and Diabetes Research Institute University of Miami Miller School of Medicine The Course
More informationTreatment to reduce cardiovascular risk: multifactorial management
Treatment to reduce cardiovascular risk: multifactorial management Matteo Anselmino, MD PhD Assistant Professor San Giovanni Battista Hospital Division of Cardiology, Department of Internal Medicine University
More informationGlucose Control and Prevention of Cardiovascular Disease
Glucose Control and Prevention of Cardiovascular Disease Dr Peter A Senior BMedSci MBBS PhD FRCP(E) Associate Professor, Director Division of Endocrinology, University of Alberta Diabetes Update+, March
More informationCardiovascular Management of a Patient with Diabetes
Cardiovascular Management of a Patient with Diabetes Dr Jeremy Krebs Clinical Leader Endocrinology and Diabetes Wellington Hospital Summary People with diabetes take a lot of medication Compliance and
More informationPhilippine Practice Guidelines for the Diagnosis & Management of Type 2 Diabetes Mellitus
Philippine Practice Guidelines for the Diagnosis & Management of Type 2 Diabetes Mellitus Iris Thiele Isip Tan MD, MSc, FPCP, FPSEM Chief, Medical Informatics Unit Associate Professor IV, UP College of
More informationMacrovascular Disease in Diabetes
Macrovascular Disease in Diabetes William R. Hiatt, MD Professor of Medicine/Cardiology University of Colorado School of Medicine President, CPC Clinical Research Conflicts CPC Clinical Research (University-based
More informationManagement of Diabetes Mellitus: A Primary Care Perspective
Management of Diabetes Mellitus: A Primary Care Perspective Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest Screening
More informationAdult Diabetes Clinician Guide NOVEMBER 2017
Kaiser Permanente National CLINICAL PRACTICE GUIDELINES Adult Diabetes Clinician Guide Introduction NOVEMBER 2017 This evidence-based guideline summary is based on the 2017 KP National Diabetes Guideline.
More informationManagement of Diabetes Mellitus: A Primary Care Perspective. Screening for Diabetes Advantages of HbA1c as a Diagnostic Test
Management of Diabetes Mellitus: A Primary Care Perspective Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest Screening
More informationPreventive Cardiology Scientific evidence
Preventive Cardiology Scientific evidence Professor David A Wood Garfield Weston Professor of Cardiovascular Medicine International Centre for Circulatory Health Imperial College London Primary prevention
More informationOld oral antidiabetic agents in the armamentarium of diabetes mellitus treatment: Safety and efficacy
Old oral antidiabetic agents in the armamentarium of diabetes mellitus treatment: Safety and efficacy Melpomeni Peppa Assistant Professor of Endocrinology 2 nd Dept of Internal Medicine-Propaedeutic, Athens
More informationDiabetes Update: Diabetes Management In Primary Care. Jonathon M. Firnhaber, MD, FAAFP
Diabetes Update: Diabetes Management In Primary Care Jonathon M. Firnhaber, MD, FAAFP Learning objectives 1. Critically evaluate the evidence emerging within diabetes research as it applies to recommendations
More informationGlycemic control A combination of life style interaction and the use of drugs
Multifactorial management to reduce cardiovascular risk in patients with diabetes mellitus Glycemic control A combination of life style interaction and the use of drugs Eberhard Standl Munich Diabetes
More information효과적인경구혈당강하제의조합은? 대한당뇨병학회제 17 차연수강좌 ( ) 가천의대길병원내분비대사내과
효과적인경구혈당강하제의조합은? 대한당뇨병학회제 17 차연수강좌 (2011.10.30.) 가천의대길병원내분비대사내과 박이병 내용 배경 경구혈당강하제의병합이왜필요한가? (WHY?) 경구혈당강하제의병합은언제시작하나? (WHEN?) 경구혈당강하제의병합은어떻게하는것이좋은가?(HOW) 맺음말 배경 : drugs for treating diabetes In 1995 :
More informationLATE BREAKING STUDIES IN DM AND CAD. Will this change the guidelines?
LATE BREAKING STUDIES IN DM AND CAD Will this change the guidelines? Objectives 1. Discuss current guidelines for prevention of CHD in diabetes. 2. Discuss the FDA Guidance for Industry regarding evaluating
More informationA factorial randomized trial of blood pressure lowering and intensive glucose control in 11,140 patients with type 2 diabetes
A factorial randomized trial of blood pressure lowering and intensive glucose control in 11,140 patients with type 2 diabetes Hypotheses: Among individuals with type 2 diabetes, the risks of major microvascular
More informationThe Metabolic Syndrome: Is It A Valid Concept? YES
The Metabolic Syndrome: Is It A Valid Concept? YES Congress on Diabetes and Cardiometabolic Health Boston, MA April 23, 2013 Edward S Horton, MD Joslin Diabetes Center Harvard Medical School Boston, MA
More informationType 2 Diabetes: Where Do We Start with Treatment? DIABETES EDUCATION. Diabetes Mellitus: Complications and Co-Morbid Conditions
Diabetes Mellitus: Complications and Co-Morbid Conditions ADA Guidelines for Glycemic Control: 2016 Retinopathy Between 2005-2008, 28.5% of patients with diabetes 40 years and older diagnosed with diabetic
More informationComplications of Diabetes: Screening and Prevention
Complications of Diabetes: Screening and Prevention Dr Steve Cleland Consultant Physician GGH and QEUH Diabetes Staff Education Course June 17 Diabetic Complications Microvascular: Retinopathy Nephropathy
More informationNewer and Expensive treatment of diabetes. Endocrinology Visiting Associate Professor Institute of Medicine TUTH
Newer and Expensive treatment of diabetes Jyoti Bhattarai MD Endocrinology Visiting Associate Professor Institute of Medicine TUTH Four out of every five people with diabetes now live in developing countries.
More informationMetformin should be considered in all patients with type 2 diabetes unless contra-indicated
November 2001 N P S National Prescribing Service Limited PPR fifteen Prescribing Practice Review PPR Managing type 2 diabetes For General Practice Key messages Metformin should be considered in all patients
More informationMedical therapy advances London/Manchester RCP February/June 2016
Medical therapy advances London/Manchester RCP February/June 2016 Advances in medical therapies for diabetes mellitus Duality of interest: The speaker or institutions with which he is associated has received
More informationManagement of Diabetes
Management of Diabetes Mellitus: Which Drugs for Which Patients? Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine baron@medicine.ucsf.edu Disclosure No relevant financial relationships
More informationType 2 Diabetes. Treat to: limit complications maintain quality of life Improve survival
Type 2 Diabetes Treat to: limit complications maintain quality of life Improve survival 1 Criteria for the diagnosis of diabetes 1. HbA1C 6.5% (rounded to 50mmol/mol). 2. FPG 7.0 mmol/l. 3. 2-h plasma
More informationManagement of Type 2 Diabetes Cardiovascular Outcomes Trials Tom Blevins MD Texas Diabetes and Endocrinology Austin, Texas
Management of Type 2 Diabetes Cardiovascular Outcomes Trials 2018 Tom Blevins MD Texas Diabetes and Endocrinology Austin, Texas Speaker Disclosure Dr. Blevins has disclosed that he has received grant support
More informationJoslin Diabetes Center Advances in Diabetes and Thyroid Disease 2013 Noninsulin Treatment of Diabetes: What the PCP Needs to Know
Non Insulin Treatment of Type 2 Diabetes: What the PCP Needs to Know Martin J. Abrahamson, MD Senior Vice President for Medical Affairs Joslin Diabetes Center Associate Professor of Medicine Harvard Medical
More informationDiabetes 2013: Achieving Goals Through Comprehensive Treatment. Session 2: Individualizing Therapy
Diabetes 2013: Achieving Goals Through Comprehensive Treatment Session 2: Individualizing Therapy Joshua L. Cohen, M.D., F.A.C.P. Professor of Medicine Interim Director, Division of Endocrinology & Metabolism
More informationINSULIN THERAPY. Rungnapa Laortanakul, MD Maharat Nakhon Ratchasima hospital
INSULIN THERAPY Rungnapa Laortanakul, MD Maharat Nakhon Ratchasima hospital 3 Sep. 2013 Case Somsak is a 64-year-old man was diagnosed with T2DM, HT, and dyslipidemia 9 years ago. No history of hypoglycemia
More informationMicrovascular Complications in Diabetes:
Microvascular Complications in Diabetes: Perspectives on Glycemic Control to Prevent Microvascular Complications Discussion Outline: Glycemia and Microvascular Compliations Clinical Trials - A Brief History
More informationWhy is Earlier and More Aggressive Treatment of T2 Diabetes Better?
Blood glucose (mmol/l) Why is Earlier and More Aggressive Treatment of T2 Diabetes Better? Disclosures Dr Kennedy has provided CME, been on advisory boards or received travel or conference support from:
More informationThe Many Faces of T2DM in Long-term Care Facilities
The Many Faces of T2DM in Long-term Care Facilities Question #1 Which of the following is a risk factor for increased hypoglycemia in older patients that may suggest the need to relax hyperglycemia treatment
More informationCASE A2 Managing Between-meal Hypoglycemia
Managing Between-meal Hypoglycemia 1 I would like to discuss this case of a patient who, overall, was doing well on her therapy until she made an important lifestyle change to lose weight. This is a common
More informationManagement of Type 2 Diabetes
Management of Type 2 Diabetes Pathophysiology Insulin resistance and relative insulin deficiency/ defective secretion Not immune mediated No evidence of β cell destruction Increased risk with age, obesity
More informationDiabetic Nephropathy 2009
Diabetic Nephropathy 2009 Michael T McDermott MD Director, Endocrinology and Diabetes Practice University of Colorado Hospital Michael.mcdermott@ucdenver.edu Diabetic Nephropathy Clinical Stages Hyperfunction
More informationDiabetes and New Meds for Cardiovascular Risk Reduction. F. Dwight Chrisman, MD, FACC. Disclosures: BI Boehringer Ingelheim speaker
Diabetes and New Meds for Cardiovascular Risk Reduction F. Dwight Chrisman, MD, FACC Disclosures: BI Boehringer Ingelheim speaker 1 Prevalence of DM DM state specific prevalence 2006 4%-6% 6-8% 8-10% 10-12%
More informationEugene Barrett M.D., Ph.D. University of Virginia 6/18/2007. Diagnosis and what is it Glucose Tolerance Categories FPG
Diabetes Mellitus: Update 7 What is the unifying basis of this vascular disease? Eugene J. Barrett, MD, PhD Professor of Internal Medicine and Pediatrics Director, Diabetes Center and GCRC Health System
More informationWhat s the Goal? Individualizing Glycemic Targets. Matthew Freeby M.D. December 3 rd, 2016
What s the Goal? Individualizing Glycemic Targets Matthew Freeby M.D. December 3 rd, 2016 Diabetes Mellitus: Complications and Co-Morbid Conditions Retinopathy Between 2005-2008, 28.5% of patients with
More informationGLP 1 agonists Winning the Losing Battle. Dr Bernard SAMIA. KCS Congress: Impact through collaboration
GLP 1 agonists Winning the Losing Battle Dr Bernard SAMIA KCS Congress: Impact through collaboration CONTACT: Tel. +254 735 833 803 Email: kcardiacs@gmail.com Web: www.kenyacardiacs.org Disclosures I have
More information9/29/2015. Primary Prevention of Heart Disease: Objectives. Objectives. What works? What doesn t?
Primary Prevention of Heart Disease: What works? What doesn t? Samia Mora, MD, MHS Associate Professor, Harvard Medical School Associate Physician, Brigham and Women s Hospital October 2, 2015 Financial
More informationThe promise of the thiazolidinediones in the management of type 2 diabetes-associated cardiovascular disease
The promise of the thiazolidinediones in the management of type 2 diabetes-associated cardiovascular disease Steve Smith, Group Director Scientific Affairs, Diabetes & Metabolism GlaxoSmithKline R & D
More informationBreaking the Cycle: Using Incretin-Based Therapies to Overcome Clinical Inertia in Type 2 Diabetes
Breaking the Cycle: Using Incretin-Based Therapies to Overcome Clinical Inertia in Type 2 Diabetes Taking It to the Next Level: Pearls for Your Clinical Practice Thursday, April 23, 2009 6:00 AM - 8:00
More informationThe Flozins Quest for Clarity?
The Flozins Quest for Clarity? Choosing Wisely with Academic Detailing 2018 ARE THEY THE REAL DEAL Disclosure statements The Academic Detailing Service is operated by Dalhousie Continuing Professional
More informationUpdate on Diabetes. Ketan Dhatariya. Why it s Not Just About Glucose Lowering Any More. Consultant in Diabetes NNUH
Update on Diabetes Why it s Not Just About Glucose Lowering Any More Ketan Dhatariya Consultant in Diabetes NNUH The Story So Far.. DCCT Retinopathy Neuropathy Nephropathy Intensive glucose control in
More informationCardiovascular Benefits of Two Classes of Antihyperglycemic Medications
Cardiovascular Benefits of Two Classes of Antihyperglycemic Medications Nathan Woolever, Pharm.D., Resident Pharmacist Pharmacy Grand Rounds November 6 th, 2018 Franciscan Healthcare La Crosse, WI 2017
More informationType 2 Diabetes Mellitus 2011
2011 Michael T. McDermott MD Director, Endocrinology and Diabetes Practice University of Colorado Hospital Michael.mcdermott@ucdenver.edu Diabetes Mellitus Diagnosis 2011 Diabetes Mellitus Fasting Glucose
More informationPrevention of MACROvascular Complications of Diabetes
Prevention of MACROvascular Complications of Diabetes Matt Bouchonville, MD, CDE Endocrinology Division University of New Mexico School of Medicine July 12, 2018 Conflicts of Interest None Objectives 1.
More informationDiabetes: Definition Pathophysiology Treatment Goals. By Scott Magee, MD, FACE
Diabetes: Definition Pathophysiology Treatment Goals By Scott Magee, MD, FACE Disclosures No disclosures to report Definition of Diabetes Mellitus Diabetes Mellitus comprises a group of disorders characterized
More informationTreating the elderly patients with type 2 diabetes mellitus
Treating the elderly patients with type 2 diabetes mellitus Niki Katsiki MSc, PhD, MD, FRSPH IASO/EASO Scope Member EASD Diabetes & Cardiovascular Disease Group Member Member of the Executive Board of
More informationReview. Hyperglycemia, dyslipidemia and hypertension in older people with diabetes: the benefits of cardiovascular risk reduction
Review Hyperglycemia, dyslipidemia and hypertension in older people with diabetes: the benefits of cardiovascular risk reduction Diabetes mellitus is increasingly recognized as an essentially vascular
More informationThe target blood pressure in patients with diabetes is <130 mm Hg
Controversies in hypertension, About Diabetes diabetes and and metabolic Cardiovascular syndrome Risk ESC annual congress August 29, 2011 The target blood pressure in patients with diabetes is
More informationFixed dose combination for Trusted Diabetes Control Lobna Farag Eltooy Head of Internal Medicine Department Assiut University
Fixed dose combination for Trusted Diabetes Control By Lobna Farag Eltooy Head of Internal Medicine Department 1 Assiut University 3/18/2018 3/18/2018 3/18/2018 Diabetes Complications with Increasing HbA1c
More informationAbbreviations DPP-IV dipeptidyl peptidase IV DREAM Diabetes REduction Assessment with ramipril and rosiglitazone
Index Abbreviations DPP-IV dipeptidyl peptidase IV DREAM Diabetes REduction Assessment with ramipril and rosiglitazone Medication GAD glutamic acid decarboxylase GLP-1 glucagon-like peptide 1 NPH neutral
More information2013 ACC AHA LIPID GUIDELINE JAY S. FONTE, MD
2013 ACC AHA LIPID GUIDELINE JAY S. FONTE, MD How do you interpret my blood test results? What are our targets for these tests? Before the ACC/AHA Lipid Guidelines A1c:
More informationGLP-1RA and insulin: friends or foes?
Tresiba Expert Panel Meeting 28/06/2014 GLP-1RA and insulin: friends or foes? Matteo Monami Careggi Teaching Hospital. Florence. Italy Dr Monami has received consultancy and/or speaking fees from: Merck
More informationGlucose Control: Does it lower CV risk?
Glucose Control: Does it lower CV risk? Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or by any means graphic,
More informationFUNDING: MICIS mandated by Maine Legislature, funded by fees collected from pharmaceutical companies as a cost of doing business in the state.
GOAL: To improve clinical outcomes by delivering upto-date, evidence-based prescribing information, using data and guidelines developed by noncommercial sources FUNDING: MICIS mandated by Maine Legislature,
More informationVascular complications
Vascular complications December 8, 2018 Faculty Disclosure Faculty: Kim Connelly, MBBS, PhD, FRACP Associate Professor of Medicine, University of Toronto Cardiologist, St. Michael s Hospital Relationships
More informationType 2 Diabetes. Stopping Smoking. Consider referral to smoking cessation. Consider referring for weight management advice.
Type 2 Diabetes Stopping Smoking Consider referral to smoking cessation BMI > 25 kg m² Set a weight loss target of a 5-10% reduction Consider referring for weight management advice Control BP to
More informationGlucose and CV disease
Glucose and CV disease Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or by any means graphic, electronic,
More informationMultiple Small Feedings of the Mind: Diabetes. Sonja K Fredrickson, MD, BC-ADM March 7, 2014
Multiple Small Feedings of the Mind: Diabetes Sonja K Fredrickson, MD, BC-ADM March 7, 2014 Question 1: Setting A1c Goals Describe the evidence based approach to determining the target HgbA1c in different
More informationDr Tahseen A. Chowdhury Royal London Hospital. New Guidelines in Diabetes: NICE or Nasty?
Dr Tahseen A. Chowdhury Royal London Hospital New Guidelines in Diabetes: NICE or Nasty? I have no conflicts of interest I do not undertake talks / advisory bodies / research for any pharma company Consultant
More informationLong-Term Complications of Diabetes Mellitus Macrovascular Complication
Long-Term Complications of Diabetes Mellitus Macrovascular Complication Sung Hee Choi MD, PhD Professor, Seoul National University College of Medicine, SNUBH, Bundang Hospital Diabetes = CVD equivalent
More informationADVANCE post trial ObservatioNal Study
Hot Topics in Diabetes 50 th EASD, Vienna 2014 ADVANCE post trial ObservatioNal Study Sophia Zoungas The George Institute The University of Sydney Rationale and Study Design Sophia Zoungas The George Institute
More informationCV Risk Management in Diabetes Mellitus
CV Risk Management in Diabetes Mellitus J R Minkoff MD, FACP Endocrinology Clinical Professor of Family and Community Medicine University of California, San Francisco Mr. B 40 y/o Latino male c/o fatigue,
More informationDr A Pokrajac MD MSc MRCP Consultant
Dr A Pokrajac MD MSc MRCP Consultant Onset at 5-15 years of T1DM Can be present at diagnosis of T2DM Detect in regular MA/Cr screening (2X first urine sample, no UTI, no other causes) Contributing Factors
More information